Table 1 Participant characteristics at baseline.
First-episode psychosis | Healthy control (N = 42) | ||
|---|---|---|---|
Placebo (N = 39) | Medication (N = 37) | ||
Age, years (SD) | 18.3 (2.7) | 18.6 (2.9) | 19.2 (3.0) |
Women, N (%) | 22 (56.4%) | 21 (56.8%) | 28 (66.7%) |
Education, years (SD) | 11.8 (1.8) | 12.0 (3.1) | 13.4 (2.2) |
Estimated IQ | 89.4 (14.1) | 91.8 (14.3) | 107.6 (10.0) |
BPRS Total, mean (SD) | 58.7 (9.1) | 57.5 (10.1) | 31.6 (3.6) |
BPRS Psychotic, mean (SD) | 15.0 (3.1) | 13.9 (3.7) | 4.1 (0.3) |
SOFAS, mean (SD) | 53.8 (13.1) | 53.3 (10.7) | 80.5 (8.9) |
SANS Total, mean (SD) | 26.8 (15.1) | 25.9 (15.0) | – |
DUP, N (%) | |||
0–30 days | 6 (15.4%) | 6 (16.2%) | – |
31–90 days | 14 (35.9%) | 12 (32.4%) | – |
>90 days | 19 (48.7%) | 19 (51.4%) | – |
Psychotic diagnosis, N (%) | |||
Major depression with psychosis | 7 (17.9%) | 8 (21.6%) | – |
Schizophreniform disorder | 6 (15.4%) | 8 (21.6%) | – |
Psychotic disorder NOS | 12 (30.8%) | 8 (21.6%) | – |
Schizophrenia | 7 (17.9%) | 5 (13.6%) | – |
Substance-induced psychotic disorder | 6 (15.4%) | 4 (10.8%) | – |
Delusional disorder | 1 (2.6%) | 4 (10.8%) | – |
